Pharma News Today (TRVN,FPRX,TTPH)

(RTTNews) - Trevena, Inc. (TRVN) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for OLINVO (oliceridine), a moderate to severe acute pain reliever injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018.

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.

Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant infections, announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous eravacycline for the treatment of complicated intra-abdominal infections.